Glenmark Pharma plans US clinical trials on biological drug
New Delhi, Sep 11 (UNI) Glenmark Pharmaceuticals today said it has filed for approval to start initial stage clinical trials of experimental biological drug GBR 500 with the US Food and Drug Administration (US FDA).
The drug is a monoclonal antibody, which Glenmark hopes to initially develop as a treatment for multiple sclerosis.
The company expects to complete the trials in the current financial year, it said in a statement.
UNI AK SY KN1136
More From
-
Karnataka Weather Alert: Pre-Monsoon Rains Likely in Bengaluru Next Week Before Summer Intensifies -
Tamil Nadu Election Dates: EC Set To Announce Polling & Counting Dates -
‘Do Not Interfere’: Donald Trump Says US Hit Iran’s Kharg Island, Warns He Will Act If Shipping Is Threatened -
Iran Nuclear Crisis: Putin’s Uranium Transfer Plan Fails to Gain US Support -
Bigg Boss Fame Vada Pav Girl Sparks Debate After Saying 'Will Sleep With Anyone For Money To Raise My Child' -
NZ vs SA T20I Series 2026: New Zealand vs South Africa Series Date, Time, Venue and Live Streaming Details -
Tamil Nadu Polls 2026: TVK Rules Out Alliance With BJP-led NDA -
What Is Google Doodle Today? The Story Behind Pi Day 2026 -
D-Mart Staff Mocks Breastfeeding Woman, Says “Doodh Piyega?” in Public; Video Goes Viral -
Japan Confirms North Korea Fired Suspected Ballistic Missile Toward East Sea, Activates Crisis Response Team -
Iran Allows Safe Passage For Two Indian LPG Carriers Through Strait Of Hormuz Amid US Conflict -
Emergency! Japan Issues Alert After Suspected North Korean Ballistic Missile Launch
Click it and Unblock the Notifications
Sign in with Google